Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2522956 | 0.93 | NPC1 (0.59) | SMN1; SMN2KDM4ETDP1LMNAHTT | |
| SCHEMBL457954 | 0.88 | NPC1 (0.73) | SMN1; SMN2KDM4ELMNAHTTNPC1 | |
| SCHEMBL11742493 | 0.85 | NPC1 (0.67) | SMN1; SMN2KDM4ETDP1LMNANPC1 | |
| SCHEMBL571063 | 0.83 | USP2 (0.69) | SMN1; SMN2KDM4ELMNAHTTNPC1 | |
| SCHEMBL6203734 | 0.82 | ALDH1A1 (0.55) | KDM4ELMNANPC1CYP1A2CYP2C9 | |
| SCHEMBL10664827 | 0.81 | KDM4E (0.64) | KDM4ELMNAKMT2AUSP2TP53 | |
| SCHEMBL31326709 | 0.81 | KDM4E (0.64) | KDM4ELMNAKMT2AUSP2TP53 | |
| SCHEMBL3099733 | 0.81 | NPC1 (0.65) | SMN1; SMN2TDP1LMNAHTTNPC1 | |
| SCHEMBL1420182 | 0.81 | NPC1 (0.65) | SMN1; SMN2LMNAHTTNPC1KMT2A | |
| SCHEMBL12637609 | 0.81 | NPC1 (0.65) | SMN1; SMN2KDM4ELMNAHTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6352994-B2 | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 2002-03-05 | — | — | US | disclosed |
| US-20010018438-A1 | Substituted 1H-pyridinyl-2-ones as GABAA alpha 2/3 ligands | MERCK SHARP & DOHME LIMITED | 2001-08-30 | — | — | US | disclosed |
| US-6200982-B1 | USEFUL IN THERAPY OF DELETERIOUS MENTAL STATES | MERCK & DOHME LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| EP-0994873-A1 | SUBSTITUTED 1H-PYRIDINYL-2-ONES AS GABA A?ALPHA 2/3 LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998055480-A1 | SUBSTITUTED 1H-PYRIDINYL-2-ONES AS GABAAALPHA 2/3 LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1998-12-10 | — | — | WO | disclosed |
| US-3940486-A | Imidazole derivatives in the treatment of pain | CIBA-GEIGY CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018438-A1 | Substituted 1H-pyridinyl-2-ones as GABAA alpha 2/3 ligands | GABRB2, GABRB3, GABRB1 | SMN1; SMN2 651/4885KDM4E 4019/4885TDP1 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.